Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Covid crawled date : 2021 - 08 - 11 save search
Global TV and Radio Broadcasting Market Report (2021 to 2030) - COVID-19 Impact and Recovery
Published: 2021-08-11 (Crawled : 18:00) - prnewswire.com
DISH | News | $5.77 -0.69% 51M
|
Consumer Services
|
| O: 0.23%
H: 0.89%
C: 0.76%
covid broadcast covid-19
I-Mab’s Antibody for Severe COVID-19 Looks Good in Interim Analysis
Published: 2021-08-11 (Crawled : 18:00) - biospace.com/
IMAB | $1.795 -0.83% -0.84% 140K
|
Health Technology
|
| O: -6.04%
H: 0.27%
C: -2.71%
covid antibody covid-19
Valneva Initiates Further Phase 3 Clinical Trial for its COVID-19 Vaccine Candidate
Published: 2021-08-11 (Crawled : 16:00) - globenewswire.com
DVAX | $11.35 -0.7% -0.7% 2.2M
|
Health Technology
|
| O: 1.28%
H: 3.29%
C: 2.45%
covid vaccine phase 3 trial covid-19
GigaGen Doses First Patient in Phase 1 Trial of Recombinant Hyperimmune Polyclonal Antibody GIGA-2050 for COVID-19First-in-human study evaluating recombinant hyperimmunes
Published: 2021-08-11 (Crawled : 15:00) - biospace.com/
GRFS | $6.53 -0.76% -0.77% 760K
|
Health Technology
|
| O: -0.14%
H: 1.09%
C: -0.55%
covid phase 1 antibody trial
Sorrento and Dyadic Announce Binding Term Sheet to License Dyadic’s Lead COVID-19 Vaccine Candidate “DYAI-100” and C1 Technology for Protein-Based Coronavirus Vaccines and Therapeutics
Published: 2021-08-11 (Crawled : 13:15) - biospace.com/
SRNE | $0.028 -8.85% 42K
|
Health Technology
|
| O: 0.0%
H: 1.36%
C: 0.68%
DYAI A | $1.605 -4.46% -4.67% 37K
|
Health Technology
|
| O: 20.33%
H: 28.7%
C: 22.22%
covid vaccine license technology
I-Mab Reports Positive Interim Analysis from Phase 2/3 Study of its GM-CSF Antibody Plonmarlimab (TJM2) to Treat Patients with Severe COVID-19
Published: 2021-08-11 (Crawled : 13:00) - biospace.com/
IMAB | $1.795 -0.83% -0.84% 140K
|
Health Technology
|
| O: -6.04%
H: 0.27%
C: -2.71%
covid phase 2 phase 2/3 positive antibody
Dyadic and Sorrento Announce Binding Term Sheet to License Dyadic’s Lead COVID-19 Vaccine Candidate “DYAI-100” and C1 Technology for Protein-Based Coronavirus Vaccines and Therapeutics
Published: 2021-08-11 (Crawled : 13:00) - globenewswire.com
SRNE | $0.028 -8.85% 42K
|
Health Technology
|
| O: 0.0%
H: 1.36%
C: 0.68%
DYAI A | $1.605 -4.46% -4.67% 37K
|
Health Technology
|
| O: 20.33%
H: 28.7%
C: 22.22%
covid vaccine license technology
Aditxt, Inc. and Great Lakes Medical Laboratory Launch AditxtScore for COVID-19 in State of Michigan as a Personalized Approach to Addressing COVID-19 Pandemic
Published: 2021-08-11 (Crawled : 13:00) - biospace.com/
ADTX | $2.37 0.85% 0.84% 55K
|
Health Technology
|
| O: -1.35%
H: 0.0%
C: -2.73%
covid covid-19
Gainers vs Losers
| 64% | 36% |
Top 10 Gainers
AGBA | $1.02 155.0% 57.94% 120M
|
Finance
ZCMD | $2.86 108.76% 52.1% 2.3M
|
Commercial Services
INVO | $1.555 104.6% 51.13% 5M
|
Health Technology
ISPC | $0.437 105.16% 49.53% 37M
|
Professional, Scientific, and T...
WLGS | $0.92 84.0% 45.65% 1.6M
|
OST | $0.499 21.38% 45.26% 1.9M
|
XPON | $3.1 60.62% 37.74% 17M
|
TIRX | $0.7 44.39% 30.74% 58M
|
BNTC | $6.92 44.17% 30.64% 3.5M
|
Health Technology
GGE | $0.035 19.86% 29.3% 64M
|
Your saved searches
Save your searches and get alerts when important news are released.